Navigation Links
NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
Date:9/22/2009

BERLIN and SAN CARLOS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented favorable data today on lead oncology program, NKTR-102, demonstrating encouraging Phase 1 and preclinical anti-tumor activity of the investigational compound in ovarian cancer. These data were presented at the European CanCer Organisation (ECCO) and the European Society for Medical Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany.

"As highlighted in our data presented today at ECCO/ESMO, we continue to see encouraging signs suggesting that NKTR-102's improved pharmacokinetics could result in an enhanced therapeutic profile," said Lorianne Masuoka, M.D., Chief Medical Officer. "We are also pleased with the rapid enrollment of the first stage of our Phase 2 clinical study in platinum-resistant ovarian cancer. Although many patients are not yet evaluable for response, we have already achieved a sufficient number of confirmed responses to open the second stage for both regimens in the study earlier than anticipated. This important new compound may offer a valuable new treatment option to overcome chemo-resistance in patients with recurrent ovarian cancer."

NKTR-102 is a novel prodrug of irinotecan that was designed using Nektar's proprietary small molecule advanced polymer conjugate technology platform. Nektar's proprietary technology is being used to significantly improve the half-life and potentially enhance the therapeutic profile of important chemotherapeutic agents and also to create novel, oral small molecule drug candidates across multiple therapeutic areas.

In the preclinical studies presented today, NKTR-102 was evaluated at three dose levels and compared to three equivalent dose levels of irinot
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
2. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
3. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
6. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
7. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
8. Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
9. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
10. Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
11. Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ciencesCorporationannouncedtodaythattherewillbemul...rationFLT3inhibitor,inAMLatthe51stAmericanSocietyo...LA,December5-8,2009.Anoralpresentationwillhighligh...tystudyinadultswithacutemyeloidleukemia(AML).Addit...heeffectofAC220monotherapyandincombinationwithchem...
(Date:11/24/2009)...FirstCall/--CardioGenicsHoldingsInc.(OTCBulletinBo...ngtheimmunoassaysegmentoftheIVDtestingmarket,repor...gtothenextphaseofthecommercializationofCardioGenic...). ,, PertheagreementwithMerckChimiethatwasexec...ewithitsproprietarysilvercoatedparamagneticbeadsfo...
(Date:11/24/2009)...Call/--EchoTherapeutics,Inc.(OTCBulletinBoard:ECTE...Systemasanon-invasive,wireless,transdermalcontinuo...inPrepSystemfortransdermaldrugdelivery,announcedto...iveOfficer,willpresentatthe13thAnnualBiotechandSpe...orkSocietyofSecuritiesAnalysts,at2:05onDecember1,2...
Breaking Medicine Technology:Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2Patch Shots May Someday Replace Injections 54893 1Patch Shots May Someday Replace Injections 54893 2Vanderbilt joins national consortium to develop new cancer therapies 54888 1Vanderbilt joins national consortium to develop new cancer therapies 54888 2Vanderbilt joins national consortium to develop new cancer therapies 54888 3American Society for Microbiology honors Anton Y Peleg 9618 1American Society for Microbiology honors Anton Y Peleg 9618 2American Society for Microbiology honors Anton Y Peleg 9618 3American Society for Microbiology honors Anton Y Peleg 9618 4
...re than 10 years, Mark Wentland, professor of chem...nic Institute , led a Rensselaer team in the disco...s with the potential to treat nervous system disor...censed to Alkermes Inc., and the company identifie...cal trials with the candidate, known as ALKS 33, b...
...en(TM), Inc. (NYSE Amex: ILE ) today announced t... ("FDA") has completed its initial review of the C...ated to its Nasolabial Fold/Wrinkles product candi...BLA for full review. , , In a communication recei...t it had completed its initial review of the Compa...
Other Medicine Technology:One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials 2One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials 3One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials 4One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials 5One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials 6Food and Drug Administration Accepts Isolagen's Biologics License Application for Full Review 2Food and Drug Administration Accepts Isolagen's Biologics License Application for Full Review 3
(Date:11/24/2009)...RNewswire/--Whiletheholidayseasonoftenbringsfamili...anbedifficultforthosegrievingthedeathofalovedone.F...milies.Theholidayseasoncanbringadditionalchallenge...ce,ACenterforGrievingChildren,AdolescentsandTheirF...ontohavingavarietyofprintandonlineresourcesavailab...
(Date:11/24/2009)...Nov.24/PRNewswire/--Bionorica,aninternationalcompa...uncedtodaytheavailabilityofneweducationalresources...th.Atipsheeton"StayingNaturallyHealthyduringtheHol...wavailableonthecompany,swebsiteat www.bionoricausa...ubscriptiontotheNaturalMomstipsheets,withcontentco...
(Date:11/24/2009)...ewswire-FirstCall/--CenteneCorporation(NYSE: CNC )...hasselectedCenteneasoneoftwoCoordinatedCareOrganiz...ssNetwork(MississippiCAN),acoordinatedcareprogramf...gwiththeDivisiontoexecuteacontractinwhichthecompan...oliaHealthPlan(Magnolia). ,, BasedinJackson,Mis...
(Date:11/24/2009)...mproves heart prospects, but cancer risk remains ,...A new study offers yet more proof that smoking is ...nd cancer. , Researchers followed 12,152 Americ...mokers and nonsmokers for three years. During that... to die of cancer, 2.26 times more likely to die o...
(Date:11/24/2009)... have found that hormones produced during pregnanc...th of breast cancer. This protein, alpha-fetoprote...ent for the treatment and prevention of breast can...evention Research , a journal of the American Asso...gnancy, such as estrogen, all induce AFP, which di...
Breaking Medicine News(10 mins):Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2Health News:Bionorica Offers Expert Resources, Health Tips for 'Natural Moms' 2Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2Health News:Smokers Double Their Risk for Heart Disease 2Health News:Protein from pregnancy hormone may prevent breast cancer 2
... N.J., April 15 MedQuist Inc. (Nasdaq: MEDQ ) t...ts new Chief Financial Officer. He joined MedQuis...t,s new CFO, Golio is responsible for directing al.... "Dominick,s broad experience as a Chief Financi...
...uck an industry trend and boost enrollments , , D...omy struggles, many health and fitness clubs conti...nchisees of Planet Fitness, however, the fastest g...ps totaling in the six figures. , , The campaign,...
...ons Give Employees More Flexibility and Ease Admin...The Guardian Life Insurance Company of America (Gu...ary benefits for small and mid-sized companies, to...rization, providing faster, easier access to impor...
...ological differences in toddlers born to drug abus...s) -- In what researchers are calling the first st...t women has been found to prompt abnormal brain de...pert said. , "If we accept the conclusion here tha...
...N.C., April 15 TSI Healthcare, a national leader ...election and implementation, and The SURVE Consult...resource firm, have announced a strategic alliance..., TSI (and its subsidiaries) currently has approxi...
...rdt and the Council for American Medical Innovatio...tion" in Chicago, featuring David Brennan, CEO of ...IO, academics and patient advocates , , CHICAGO,...atient advocacy to address the importance of medic...
Other Medicine News:Health News:MedQuist Names Dominick J. Golio as Chief Financial Officer 2Health News:Despite Ailing Economy, Planet Fitness Thrives 2Health News:New Program Gives Guardian Dental Pre-Paid/DHMO Members Greater Access to Specialty Care 2Health News:Fetal Exposure to Methamphetamine May Harm Child's Brain 2Health News:TSI Healthcare and SURVE Consulting Announce a Strategic Alliance for Leadership and Business Development 2Health News:Chicago's Top Minds Join National Business and Health Leaders in Addressing Medical Innovation, Highlighting Policies Needed to Maintain U.S. Competitiveness in Medical Science and Discovery 2Health News:Chicago's Top Minds Join National Business and Health Leaders in Addressing Medical Innovation, Highlighting Policies Needed to Maintain U.S. Competitiveness in Medical Science and Discovery 3Health News:Chicago's Top Minds Join National Business and Health Leaders in Addressing Medical Innovation, Highlighting Policies Needed to Maintain U.S. Competitiveness in Medical Science and Discovery 4
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: